Moleculin Biotech (MBRX) Expected to Announce Quarterly Earnings on Friday

Moleculin Biotech (NASDAQ:MBRX) is anticipated to release its Q4 2025 results before the market opens on Friday, March 20th. Analysts expect Moleculin Biotech to post earnings of ($7.77) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, March 18, 2026 at 7:00 AM ET.

Moleculin Biotech Stock Down 3.7%

NASDAQ:MBRX opened at $2.08 on Thursday. Moleculin Biotech has a 12-month low of $1.79 and a 12-month high of $33.00. The stock’s fifty day simple moving average is $3.48 and its 200-day simple moving average is $7.17. The firm has a market capitalization of $4.24 million, a P/E ratio of -0.06 and a beta of 1.73.

Institutional Trading of Moleculin Biotech

An institutional investor recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC purchased a new stake in Moleculin Biotech, Inc. (NASDAQ:MBRX) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned approximately 1.11% of Moleculin Biotech as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 15.52% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on MBRX. HC Wainwright restated a “buy” rating and set a $22.00 target price (up from $4.00) on shares of Moleculin Biotech in a report on Thursday, December 11th. Roth Mkm reaffirmed a “buy” rating on shares of Moleculin Biotech in a research note on Monday, December 15th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Moleculin Biotech in a research report on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $61.00.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.